The guideline, titled "Care of the Patient with Primary Open-Angle Glaucoma," was developed by the AOA Evidence-based Optometry Guideline Development Group.

The company's lead product candidate Duravyu (vorolanib intravitreal insert), f/k/a EYP-1901, is anticipating topline data from several clinical trials in 2026.

The investigators used National Health and Nutrition Examination Survey data in a cross-sectional study to determine the association between Dietary Inflammatory Index and non-refractive visual impairment from diseases other than cataract and age-related macular degeneration.

Whitecap is currently developing 2 therapies for potential use in glaucoma and geographic atrophy.

The company will prioritize its cash in funding its ongoing Phase 1/2 PRISM clinical trial and Phase 3 4FRONT program.

The webinar will overview new offerings, details about the show’s updated brand and new exhibit hall layout, special events, and announcements regarding this year’s keynote speaker and other main stage sessions.

The new standards touch on alignment, terminology, expectations, and adherence, according to the council.

Nocturnal hypoxia could be a new additional modifiable risk factor for nAMD.

With this addition, Zeiss completes the Corneal Refractive Workflow, which already includes Visumax 800 and SMILE pro.

The application was refiled following a December 20, 2024, meeting between the US Food and Drug Administration (FDA) and Astellas.

Katie Rachon, OD, FAAO, Dipl ABO, shares her excitement for the upcoming conference and what it means for an optometrist's toolbox.

Catch up on what happened in optometry during the week of January 6-January 10.

The educational resources is now being used in 64% of the world's countries, with the US, the United Kingdom, Malaysia, India, Australia, and Canada as the most frequent users.

The module provides eye care professionals access to advanced thickness mapping and data insights for evaluating epithelial and stromal structures.

A recent study evaluated both deep neural networks and aggregation functions to determine ways to improve schizophrenia detection.

The 3-arm, multicenter, randomized, double masked, safety and efficacy study successfully met pre-specified visual acuity primary endpoints with statistically significant near vision improvements recorded at all time points over 8 hours.

Educational material available include downloadable fact sheets, glaucoma financial assistance resources, shareable social media graphics, and a dedicated webpage.

The campaign will spotlight educational resources and share stories of individuals and families living with glaucoma to raise awareness and encourage proactive eye health management.

The primary safety endpoint was carried out through the percentage of patients with shift from normal (at baseline) to abnormal in any electrocardiogram (ECG).